Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-Risk Classical Hodgkin Lymphoma.
Zufei ZhangDaping ZhangWenchuan GuoKeenan FentonSujata NarayananShweta JainJoy JiangSharon M CastellinoKara M KellyPeter D ColeFrank G KellerAmit GargYen Lin ChiaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
No further adjustments based on age or BW are required for the BV dose (1.8 mg/kg Q3W) approved in children.